Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab

Journal of the American Academy of Dermatology

Volumn 67, Issue 5, 2012, Pages e237-e238

  Goldminz, Ari M ^a   Botto, Nina C ^a   Gottlieb, Alice B ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; GLUCOCORTICOID; MONOCLONAL ANTIBODY; PREDNISONE; USTEKINUMAB;

CASE REPORT; HUMAN; LETTER; MALE; MIDDLE AGED; PYODERMA GANGRENOSUM;

ANTIBODIES, MONOCLONAL; DAPSONE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PREDNISONE; PYODERMA GANGRENOSUM;

EID: 84872683372     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.04.045     Document Type: Article

References (4)

1. Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma gangrenosum: A review and update on new therapies. J Am Acad Dermatol 2010;62:646-654.
2. Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: An evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005;53:273-283.
3. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: A randomized, double blind, placebo controlled trial. Gut 2006;55:505-509.
4. Guenova E, Teske A, Fehrenbacher B, Hoerber S, Adamczyk A, Schaller M, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol 2011;147:1203-1205.